| Literature DB >> 31182547 |
Joseph Castillo1, Esther Wu1, Christopher Lowe2, Shrividhya Srinivasan1, Ron McCord1, Marie-Claire Wagle1, Sangeeta Jayakar3, Melissa Gonzalez Edick3, Jeffrey Eastham-Anderson3, Bonnie Liu1, Katherine E Hutchinson1, Wendell Jones4, Matthew P Stokes5, Somayeh S Tarighat1, Thomas Holcomb1, Andrew Glibicky1, F Anthony Romero6, Steven Magnuson6, Shih-Min A Huang1, Vicki Plaks2, Jennifer M Giltnane3, Mark R Lackner1, Zineb Mounir7.
Abstract
Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms by which CBP/p300 regulate Treg differentiation and the consequences of CBP/p300 loss-of-function mutations in follicular lymphoma. Transcriptional and epigenetic profiling identified a cascade of transcription factors essential for Treg differentiation. Mass spectrometry analysis showed that CBP/p300 acetylates prostacyclin synthase, which regulates Treg differentiation by altering proinflammatory cytokine secretion by T and B cells. Reduced Treg presence in tissues harboring CBP/p300 loss-of-function mutations was observed in follicular lymphoma. Our findings provide novel insights into the regulation of Treg differentiation by CBP/p300, with potential clinical implications on alteration of the immune landscape. SIGNIFICANCE: This study provides insights into the dynamic role of CBP/p300 in the differentiation of Tregs, with potential clinical implications in the alteration of the immune landscape in follicular lymphoma. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31182547 DOI: 10.1158/0008-5472.CAN-18-3622
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701